VCYT — Veracyte, Inc.
Is VCYT overbought or oversold? Here is the current MarketMoodz read.
Veracyte, Inc. (VCYT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $24.23. The rating moved from Neutral to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$24.23
- Last changeMoved from Neutral to Oversold on November 16, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
Veracyte, Inc. (VCYT) is a genomic diagnostics company with differentiated tests serving thyroid and lung diagnostic pathways and a growing addressable oncology testing market. The company benefits from established clinical adoption, recurring per-test revenue, and the potential to scale margins as volumes increase. Near-term catalysts include incremental payer wins, expanded guideline recognition, and successful commercialization of new assays or channels. Key vulnerabilities include heightened Medicare Advantage regulatory scrutiny that could affect reimbursement and utilization, competitive pressures from other molecular diagnostics, and the need to demonstrate durable margin improvement and execution against commercialization plans. With limited social and EDGAR signal in the provided inputs, the outlook depends on continued adoption, payer outcomes, and operational execution across the next quarters.
Key factors
- Established genomic diagnostics franchise with recognized products addressing thyroid and lung cancer diagnostic workflows
- Large and growing addressable market driven by oncology diagnostic adoption, expanded guideline recognition and potential payer coverage improvements
- Recurring revenue characteristics tied to test volume and expanding provider adoption; potential for margin expansion as fixed costs scale
- Partnerships and commercial execution that can accelerate distribution into community and specialty practices
- Limited near‑term macro/regulatory noise in markets supports selective growth names rather than broad risk‑off flows
Risks
- Medicare Advantage and CMS program integrity tightening could increase reimbursement scrutiny, lead to clawbacks or slower payer approvals for certain diagnostic claims
- Reimbursement pressure or reduced utilization from payors limiting uptake or pricing for diagnostic tests
- Competition from other molecular diagnostics and emerging technologies that could compress market share or pricing
- Execution risk around new product launches, salesforce productivity and maintaining growth while improving unit economics
- Volatility from broader growth-stock sentiment and selective sector flows that could disproportionally impact smaller-cap diagnostics names
- Limited publicly available near-term filings or social sentiment data to validate recent operational trends
See today's live rating, score and targets
Members see the live hourly rating for VCYT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.